Sitagliptin/Metaformin Hydrochloride Sustained-release Tablets

Formulation (FDF) · Sustained-release Tablets · 50mg/500mg; 50mg/850mg

Formulation (FDF)Confidentiality：Public

INN / Generic Name: Sitagliptin/Metaformin Hydrochloride Sustained-release Tablets
Dosage Form: Sustained-release Tablets
Strength: 50mg/500mg; 50mg/850mg
Therapy Area: Metabolic & Endocrinology
Indication: Type 2 diabetes mellitus
Current Status: Official FDF licensing catalog (UB213)
GMP Certification: US - FDA; CN - NMPA
CEP: No
DMF Type: —
Stability Data: —
BE Required: Not required / waivable
Registration Pathway: Registered (market rights transferable / DCP·NP per market)
MOQ: On request
Lead Time: On request
Price Range: On request

HS Code

3004.903 customs bills on file

Registrable Markets

China

Process / Sequence / Exact Price